Shots:
- Gilead has reported topline P-III (ASCENT-03) trial data (n=~540) assessing Trodelvy vs CT in 1L pts with locally advanced, inoperable, or metastatic TNBC without PD-L1 expression or PD-L1+ pts who are previously treated with a PD-L1 inhibitor
- Trial met its 1EP of improved PFS in treatment-naïve mTNBC pts ineligible for PD-1/PD-L1 inhibitors; OS (2EP) data is immature & will be assessed later, with no detriment observed till now. Data to be shared with global health authorities
- Trodelvy is being evaluated in P-III (ASCENT-07) trial for HR+/HER2- mBC post-endocrine therapy, P-III (ASCENT-04) trial for mTNBC, P-III (ASCENT-05) trial for early-stage TNBC, & multiple P-III trials in lung & gynecologic cancers; ASCENT-04 data to be shared at ASCO 2025
Ref: Gilead | Image: Gilead| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
